RMD · Resmed Inc
$224.46
-2.28 (-1.01%)
At close · Aug 14
Market Cap
$32.38B
Shares
144.25M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Farrell | Chief executive officer | $14,674,543 |
| Justin Leong | Chief product officer | $3,911,441 |
| Bobby Ghoshal | Chief commercial officer, Residential Care Software | $3,652,455 |
| Brett Sandercock | Chief financial officer | $3,572,010 |
| Mike Rider | Global general counsel and secretary | $2,289,122 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Farrell | Chief executive officer | $14,120,829 |
| Justin Leong | Chief product officer | $3,597,240 |
| Bobby Ghoshal | Chief commercial officer, SaaS Justin Leong(g) | $3,530,870 |
| Brett Sandercock | Chief financial officer | $3,233,565 |
| Mike Rider | Global general counsel and secretary | $2,154,393 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Farrell | Chief executive officer | $13,868,641 |
| Rob Douglas | President and chief operating officer | $6,673,987 |
| Lucile Blaise | President - Sleep and respiratory care business | $3,496,969 |
| Bobby Ghoshal | Chief commercial officer, SaaS Justin Leong(g) | $3,309,520 |
| Brett Sandercock | Chief financial officer | $3,109,690 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Farrell | Chief executive officer | $11,659,215 |
| Rob Douglas | President and chief operating officer | $6,320,888 |
| Brett Sandercock | Chief financial officer | $2,891,331 |
| Bobby Ghoshal | Chief commercial officer, SaaS Justin Leong(g) | $2,860,063 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Rob Douglas | President and chief operating officer | $6,440,661 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Aaron Bloomer | Chief Financial Officer | Appointed | 2026-04-30 |
| Richard Sulpizio | director | Terminated | 2025-11-20 |
| Nicole Mowad-Nassar | Board of Directors | Appointed | 2025-08-18 |
| Bobby Ghoshal | chief commercial officer, residential care software business ("RCS") | Resigned | 2025-08-01 |
| Christopher DelOrefice | board of directors | Appointed | 2024-08-16 |
| Katrin Pucknat | Chief Marketing Officer | Appointed | 2023-11-09 |
| Mike Fliss | Chief Revenue Officer | Appointed | 2023-11-09 |
| Lucile Blaise | senior vice president, strategy & business development | Appointed | 2023-11-09 |
| Justin Leong | Chief Product Officer | Appointed | 2023-11-09 |
| Robert Douglas | chief operating officer and president | Retired | 2023-11-09 |
| David Pendarvis | chief administrative officer | Retired | 2023-03-30 |
| Amy Wakeham | Chief Communications and Investor Relations Officer | Appointed | 2023-03-30 |
| David Pendarvis | global general counsel | Retired | 2023-03-30 |
| Peter C. Farrell | chair emeritus | Appointed | 2023-01-26 |
| Michael J. "Mick" Farrell | chair of our board of directors | Appointed | 2023-01-26 |
| Robert Douglas | Interim President, Sleep and Respiratory Care Business | Terminated | 2022-07-01 |
| Lucile Blaise | President, Sleep and Respiratory Care Business | Appointed | 2022-07-01 |
| Robert ("Rob") Douglas | interim president – sleep and respiratory care business | Appointed | 2022-05-11 |
| Jim Hollingshead | president – sleep and respiratory care business | Resigned | 2022-05-11 |
Key facts
CIK
943819
CUSIP
761152107
13F (30d)
803 filings
771 filers
Visit website
Investor relations